News

Public · Published

Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation

Ardelyx, a commercial-stage biopharmaceutical company, said it fully enrolled all patients ahead of schedule in its Phase 3 ACCEL trial testing IBSRELA (tenapanor) for chronic idiopathic constipation in adults. Topline data is expected in the second half of 2027.

Published:

Updated:

What happened

Ardelyx, a commercial-stage biopharmaceutical company, said it fully enrolled all patients ahead of schedule in its Phase 3 ACCEL trial testing IBSRELA (tenapanor) for chronic idiopathic constipation in adults. Topline data is expected in the second half of 2027.

Confirmed

Global impact / market context

Faster enrollment moves the company closer to possible regulatory filing and eventual revenue, but the path is long: results arrive only in 2027, and the drug must still show safety and efficacy. Success could widen IBSRELA's label beyond its current use.

Analyst inference

Investors weighing Ardelyx are balancing trial speed against the cash cost of running late-stage studies with no near-term data. Any capital spending must be funded from existing sales, borrowed money, or stock, so cash available and future trial costs matter.

Analyst inference

What to watch

  1. Topline results from the Phase 3 ACCEL trial are expected in the second half of 2027, so the next major information event is roughly a year or more away. Confirmed
  2. Watch whether Ardelyx submits a regulatory filing for IBSRELA in chronic idiopathic constipation after topline data, which would be a proposal until the company confirms it. Proposed
  3. Track research and development spending and cash available each quarter, since running the trial raises costs before any possible new revenue from a wider IBSRELA label. Analyst inference

Evidence